EC Number |
Source Tissue |
Reference |
---|
2.1.1.67 | A-172 cell |
- |
720847 |
2.1.1.67 | astrocyte |
primary cell |
720847 |
2.1.1.67 | astroglial cell |
- |
720847 |
2.1.1.67 | blood |
- |
485516, 485520, 485523, 485524, 485526, 485527, 684265, 684733, 685852, 685945, 686157, 686161, 686184, 686326, 686505, 686507, 687983, 688452, 689358, 689368, 689369, 690115, 690118, 701941, 703267, 703275, 703931, 704829, 756499, 756597 |
2.1.1.67 | colon carcinoma cell |
- |
703564 |
2.1.1.67 | embryonic kidney cell line |
embryonic kidney cell line with inducible thiopurine methyltransferase |
685037 |
2.1.1.67 | erythrocyte |
- |
485516, 485518, 485520, 485522, 485523, 485524, 485525, 485526, 485527, 657544, 659566, 685852, 685945, 686157, 686184, 686275, 686326, 686351, 686505, 686507, 686574, 687983, 689358, 689362, 689368, 689369, 690115, 690118, 702164, 702940, 703355, 704818, 704932, 705450, 706091, 706092, 706093, 706816, 718804, 733706, 733775, 734843, 755922, 756145, 756497, 757309, 757473 |
2.1.1.67 | erythrocyte |
from patients with chronic inflammatory bowel disease |
658654 |
2.1.1.67 | erythrocyte |
TPMT activity is significantly lower in patients with acute lymphoblastic leukemia compared to control. Increase of TPMT activity during maintainance treatment with 6-mercaptopurine and already after induction therapy (treatment with antifolates, e.g. methotrexate and trimethoprim), before the patients receive 6-mercaptopurine |
658653 |
2.1.1.67 | erythrocyte |
TPMT phenotyping |
686161 |